Skip to main content

Table 2 Overview of affinity/avidity data of candidate therapeutic antibodies

From: A walk through tau therapeutic strategies

ANTIBODY EPITOPE AFFINITY AVIDITY TARGET (IN SPR) NOTE REFERENCE
HJ8.5 aa25-30 nd. 0.4 pM Human Tau2N4R tau immobilized to a high level (> 3000 RU) [375]
HJ9.4 aa7-13 nd. 7 nM Human Tau2N4R tau immobilized to a high level (> 3000 RU) [375]
HJ9.3 aa306-320 nd. 100 pM Human Tau2N4R tau immobilized to a high level (> 3000 RU) [375]
ACI-5400 aa393-408(pS396) 38 nM nd. Tau393-408(pS396/pS404) tau immobilized to a low level (130 RU) [321]
DC8E8 Tetratope in the repeat region of tau (aa268-367) 91 nM nd. Human Tau2N4R Antibody immobilized to a low level (230-250 RU) [168]
DC8E8 Tetratope in the repeat region of tau (aa268-367) 14 nM nd. Pathological Tau151-391_4R Antibody immobilized to a low level (230-250 RU) [168]
derived from MC1 aa7-9; aa312-322 235 nd. monomeric tau Antibody immobilized at unknown density [135]
derived from MC1 aa7-9; aa312-322 nd. < 0.22 nM tau aggregate Antibody immobilized at unknown density [135]
  1. nd Not defined, SPR Surface plasmon resonance spectroscopy